Eilien Heinrich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eilien Heinrich has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra K. Kiemer
Department of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, Germany
3 shared publications - Gregor Fuhrmann
Department of Biology, Pharmaceutical Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
3 shared publications - Adriely Goes
Helmholtz Centre for Infection Research (HZI), Biogenic Nanotherapeutics Group (BION), Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus E8.1, 66123 Saarbrücken, Germany
2 shared publications Marcus Koch
INM – Leibniz Institute for New Materials Campus D2 2 66123 Saarbrücken Germany
2 shared publications- Rolf Müller
Saarland University
2 shared publications Arefeh Kardani
Helmholtz‐Institute for Pharmaceutical Research Saarland (HIPS) Helmholtz‐Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany
1 shared publication
Latest Publications
- Open Access
- 16 August 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (36) , 26388-26399
Design and characterisation of casein coated and drug loaded magnetic nanoparticles for theranostic applications
Magnetic protein-coated, drug-loaded nanohybrids have huge potential in future cancer theranostics for real-time monitored drug delivery.
- 16 August 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (36) , 26388-26399
Open AccessDesign and characterisation of casein coated and drug loaded magnetic nanoparticles for theranostic applications
Magnetic protein-coated, drug-loaded nanohybrids have huge potential in future cancer theranostics for real-time monitored drug delivery.
- Open Access
Cell‐Derived Vesicles for Antibiotic Delivery—Understanding the Challenges of a Biogenic Carrier System
Recently, extracellular vesicles (EVs) sparked substantial therapeutic interest, particularly due to their ability to mediate targeted transport between tissues and cells. Yet, EVs’ technological translation as therapeutics strongly depends on better biocompatibility assessments in more complex models and elementary in vitro–in vivo correlation, and comparison of mammalian versus bacterial vesicles. With this in mind, two new types of EVs derived from human B‐lymphoid cells with low immunogenicity and from non‐pathogenic myxobacteria SBSr073 are introduced here. A large‐scale isolation protocol to reduce plastic waste and cultivation space toward sustainable EV research is established. The biocompatibility of mammalian and bacterial EVs is comprehensively evaluated using cytokine release and endotoxin assays in vitro, and an in vivo zebrafish larvae model is applied. A complex three‐dimensional human cell culture model is used to understand the spatial distribution of vesicles in epithelial and immune cells and again used zebrafish larvae to study the biodistribution in vivo. Finally, vesicles are successfully loaded with the fluoroquinolone ciprofloxacin (CPX) and showed lower toxicity in zebrafish larvae than free CPX. The loaded vesicles are then tested effectively on enteropathogenic Shigella, whose infections are currently showing increasing resistance against available antibiotics.
Open AccessCell‐Derived Vesicles for Antibiotic Delivery—Understanding the Challenges of a Biogenic Carrier System
Recently, extracellular vesicles (EVs) sparked substantial therapeutic interest, particularly due to their ability to mediate targeted transport between tissues and cells. Yet, EVs’ technological translation as therapeutics strongly depends on better biocompatibility assessments in more complex models and elementary in vitro–in vivo correlation, and comparison of mammalian versus bacterial vesicles. With this in mind, two new types of EVs derived from human B‐lymphoid cells with low immunogenicity and from non‐pathogenic myxobacteria SBSr073 are introduced here. A large‐scale isolation protocol to reduce plastic waste and cultivation space toward sustainable EV research is established. The biocompatibility of mammalian and bacterial EVs is comprehensively evaluated using cytokine release and endotoxin assays in vitro, and an in vivo zebrafish larvae model is applied. A complex three‐dimensional human cell culture model is used to understand the spatial distribution of vesicles in epithelial and immune cells and again used zebrafish larvae to study the biodistribution in vivo. Finally, vesicles are successfully loaded with the fluoroquinolone ciprofloxacin (CPX) and showed lower toxicity in zebrafish larvae than free CPX. The loaded vesicles are then tested effectively on enteropathogenic Shigella, whose infections are currently showing increasing resistance against available antibiotics.
- 17 November 2022
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 14 (47) , 17534-17542
The inherent antibiotic activity of myxobacteria-derived autofluorescent outer membrane vesicles is switched on and off by light stimulation
Outer membrane vesicles are small, lipid-based vesicles shed from the outer membrane of Gram-negative bacteria.
- 17 November 2022
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 14 (47) , 17534-17542
The inherent antibiotic activity of myxobacteria-derived autofluorescent outer membrane vesicles is switched on and off by light stimulation
Outer membrane vesicles are small, lipid-based vesicles shed from the outer membrane of Gram-negative bacteria.
- Open Access
Myxobacteria-Derived Outer Membrane Vesicles: Potential Applicability Against Intracellular Infections
In 2019, it was estimated that 2.5 million people die from lower tract respiratory infections annually. One of the main causes of these infections is Staphylococcus aureus, a bacterium that can invade and survive within mammalian cells. S. aureus intracellular infections are difficult to treat because several classes of antibiotics are unable to permeate through the cell wall and reach the pathogen. This condition increases the need for new therapeutic avenues, able to deliver antibiotics efficiently. In this work, we obtained outer membrane vesicles (OMVs) derived from the myxobacteria Cystobacter velatus strain Cbv34 and Cystobacter ferrugineus strain Cbfe23, that are naturally antimicrobial, to target intracellular infections, and investigated how they can affect the viability of epithelial and macrophage cell lines. We evaluated by cytometric bead array whether they induce the expression of proinflammatory cytokines in blood immune cells. Using confocal laser scanning microscopy and flow cytometry, we also investigated their interaction and uptake into mammalian cells. Finally, we studied the effect of OMVs on planktonic and intracellular S. aureus. We found that while Cbv34 OMVs were not cytotoxic to cells at any concentration tested, Cbfe23 OMVs affected the viability of macrophages, leading to a 50% decrease at a concentration of 125,000 OMVs/cell. We observed only little to moderate stimulation of release of TNF-alpha, IL-8, IL-6 and IL-1beta by both OMVs. Cbfe23 OMVs have better interaction with the cells than Cbv34 OMVs, being taken up faster by them, but both seem to remain mostly on the cell surface after 24 h of incubation. This, however, did not impair their bacteriostatic activity against intracellular S. aureus. In this study, we provide an important basis for implementing OMVs in the treatment of intracellular infections.
Open AccessMyxobacteria-Derived Outer Membrane Vesicles: Potential Applicability Against Intracellular Infections
In 2019, it was estimated that 2.5 million people die from lower tract respiratory infections annually. One of the main causes of these infections is Staphylococcus aureus, a bacterium that can invade and survive within mammalian cells. S. aureus intracellular infections are difficult to treat because several classes of antibiotics are unable to permeate through the cell wall and reach the pathogen. This condition increases the need for new therapeutic avenues, able to deliver antibiotics efficiently. In this work, we obtained outer membrane vesicles (OMVs) derived from the myxobacteria Cystobacter velatus strain Cbv34 and Cystobacter ferrugineus strain Cbfe23, that are naturally antimicrobial, to target intracellular infections, and investigated how they can affect the viability of epithelial and macrophage cell lines. We evaluated by cytometric bead array whether they induce the expression of proinflammatory cytokines in blood immune cells. Using confocal laser scanning microscopy and flow cytometry, we also investigated their interaction and uptake into mammalian cells. Finally, we studied the effect of OMVs on planktonic and intracellular S. aureus. We found that while Cbv34 OMVs were not cytotoxic to cells at any concentration tested, Cbfe23 OMVs affected the viability of macrophages, leading to a 50% decrease at a concentration of 125,000 OMVs/cell. We observed only little to moderate stimulation of release of TNF-alpha, IL-8, IL-6 and IL-1beta by both OMVs. Cbfe23 OMVs have better interaction with the cells than Cbv34 OMVs, being taken up faster by them, but both seem to remain mostly on the cell surface after 24 h of incubation. This, however, did not impair their bacteriostatic activity against intracellular S. aureus. In this study, we provide an important basis for implementing OMVs in the treatment of intracellular infections.